Khurram Jamil sold $232k of GALT
Chief Medical Officer at GALECTIN THERAPEUTICS INC. 60,000 shares at an average of $3.87, traded Jan 2, 2026, filed Jan 6, 2026.
Score components
- +15RoleOfficer
- +13Trade size$232k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -18.0%, 3m -36.5%, 6m +33.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001133416-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | MOption exercise Common Stock10b5-1 | +60,000 | $0.00 | $0 | 60,000 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -13,055 | $4.20 | $55k | 46,945 | Jan 6, 2026 |
| Jan 5, 2026 | SOpen-market sale Common stock10b5-1 | -25,499 | $3.90 | $99k | 21,446 | Jan 6, 2026 |
| Jan 6, 2026 | SOpen-market sale Common Stock10b5-1 | -21,446 | $3.65 | $78k | 0 | Jan 6, 2026 |
| Jan 1, 2026 | MOption exercise Restricted Stock Unitderivative10b5-1 | -60,000 | $0.00 | $0 | 0 | Jan 6, 2026 |
Related signals
Other insiders at GALECTIN THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 9Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $83k 16,250 shares | -100% | |
| 21Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $262k 52,037 shares | -2555% | |
| 19Weak | GALECTIN THERAPEUTICS INC | Harold H. Shlevin director | $151k 30,000 shares | -211% | |
| 8Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $24k 7,557 shares | -100% | |
| 0Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $1,761 568 shares | -100% | |
| 23Weak | GALTbuy GALECTIN THERAPEUTICS INC | Kary Eldred director | $810 300 shares | +0% | |
| 35Weak | GALECTIN THERAPEUTICS INC | Jack W Callicutt Chief Financial Officer | $233k 60,000 shares | -89% | |
| 19Weak | GALECTIN THERAPEUTICS INC | Joel Lewis President and CEO | $321k 84,000 shares | -9% | |
| 21Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $33k 8,125 shares | -100% | |
| 16Weak | GALECTIN THERAPEUTICS INC | Kary Eldred director | $2,611 700 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.